1. Home
  2. TALK vs DBVT Comparison

TALK vs DBVT Comparison

Compare TALK & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Talkspace Inc.

TALK

Talkspace Inc.

HOLD

Current Price

$3.52

Market Cap

442.1M

Sector

Health Care

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$22.56

Market Cap

508.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TALK
DBVT
Founded
2012
2002
Country
United States
France
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
442.1M
508.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TALK
DBVT
Price
$3.52
$22.56
Analyst Decision
Strong Buy
Buy
Analyst Count
3
7
Target Price
$4.83
$31.75
AVG Volume (30 Days)
1.2M
723.1K
Earning Date
10-30-2025
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.03
N/A
Revenue
$214,593,000.00
$5,502,000.00
Revenue This Year
$23.86
$1,768.71
Revenue Next Year
$22.22
$1,028.88
P/E Ratio
$140.51
N/A
Revenue Growth
18.37
N/A
52 Week Low
$2.22
$2.74
52 Week High
$4.36
$26.19

Technical Indicators

Market Signals
Indicator
TALK
DBVT
Relative Strength Index (RSI) 60.73 73.91
Support Level $3.43 $20.27
Resistance Level $3.67 $26.19
Average True Range (ATR) 0.14 1.73
MACD 0.03 0.74
Stochastic Oscillator 78.69 74.17

Price Performance

Historical Comparison
TALK
DBVT

About TALK Talkspace Inc.

Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: